secwatch.observer — SEC 8-K summary
======================================

Issuer:     Marker Therapeutics, Inc. (MRKR)
CIK:        0001094038
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001104659-22-117148
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Marker Therapeutics Q3 net loss narrows to $6.9M; FDA grant awarded for AML trial
--------------------------------------------------------------------------------

- Net loss of $6.9M in Q3 2022, compared to $12.4M loss in Q3 2021.
- Cash and equivalents $18.1M as of Sept 30, 2022; grant income $1.0M, related party service revenue $2.95M.
- Awarded $2M FDA Orphan Products Grant to support Phase 2 ARTEMIS trial of MT-401 in post-transplant AML.
- All six patients in Cohorts 4/5 treated with new manufacturing process; no DLTs; efficacy data expected by year-end.
- FDA cleared IND for Phase 1 MT-601 in relapsed/refractory non-Hodgkin lymphoma; first patient expected Q1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1094038/000110465922117148/0001104659-22-117148-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1094038/000110465922117148/tm2223865d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-117148

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer